Aceragen Inc
ACGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.24M
Close$
Share Statistics
| Market cap | $3.24 Million |
|---|---|
| Enterprise Value | $1.67 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.17 |
| Beta | 1.14 |
| Outstanding Shares | 5,352,900 |
Return
| Return on Equity | -49.27% |
|---|---|
| Return on Assets | -18.97% |
| Return on Invested Capital | -9.31% |
Valuation & Multiples
| P/E Ratio | -0.06 |
|---|---|
| PEG | 0.06 |
| Price to Sales | - |
| Price to Book Ratio | 0.05 |
| Enterprise Value to Revenue | 0.34 |
| Enterprise Value to EBIT | -0.22 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 6.28 |
| Debt to Equity | 0.27 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Aceragen Inc
32 employees
CEO: Vincent Milano Harnessing the approach of the earliest researchers in immunotherapy and the company's vast experience in developing proprietary immunology platforms, Idera's development program is focused on priming the immune system to play a more pow...